Navigation Links
Optimize Transfection of siRNAs for RNAi

hat siRNA-mediated reduction in mRNA increases with increasing volumes of transfection agent. A midpoint volume of 3 l per well was used for all remaining experiments.

Figure 3. Cytotoxicity of Transfection Agent/siRNA complexes. COS-7 cells were plated into wells of a 24 well plate at 3.0 x 104 cells per well approximately 24 hr prior to transfection. Complexes containing negative control siRNA (10 nM) and various amounts of siPORT Amine Transfection Agent were added to the wells. After transfection (48 hr), cells were washed, trypsinized, and stained with 10% Trypan Blue. Cells were subsequently counted and percent cell survival was calculated as: (Total number of cells - Number of stained cells) / Total number of cells x 100.

Figure 4. Determination of Optimal Amount of Transfection Agent. COS-7 cells grown in a 24 well dish were transfected with 10 nM GAPDH siRNA or negative control siRNA 24 hours after plating at the optimized cell plating density (3.0 x 104 cells per well) using 2, 3, or 4 l siPORT Amine Transfection Agent per well. 48 hours following transfection, the cells were harvested and analyzed by real-time RT-PCR for both GAPDH mRNA and 18S rRNA levels. Percent gene expression was calculated as a percentage of gene expression compared to the negative control siRNA.


Effect of siRNA Concentration on Transfection. We tested several siRNA concentrations to establish the amount required to achieve >50% mRNA reduction. Increasing amounts of GAPDH siRNA (3, 10, 30, and 100 nM) and negative controls were tested with t
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Optimized Imaging of Protein Gels Stained with Coomassie Brilliant Blue Dye
2. Eagle Eye Optical Filter Optimized for Imaging Silver-Stained Gels
3. Optimized Dengue RT-PCR
4. Rapamycin Optimized in 100 Liter Fermentor Using BioCommand Control Strategys
5. Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell Line
6. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
7. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
8. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
9. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
10. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
11. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Optimize Transfection siRNAs for RNAi

(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... of Compensatory Award Will Now Proceed -, MADISON, N.J., ... its motion for judgment as a matter of law on ... Scroggin v.,Wyeth, in the U.S. District Court, Eastern District of ... punitive damages award of,$19,360,000 rendered by the Little Rock jury ...
... USA Study to Evaluate Treatment of Coronary Artery Disease ... Patients in Real-World Setting, ... of the XIENCE V(TM) USA post-approval study, with six,hospital centers already ... Drug Administration approved the XIENCE V(TM),Everolimus Eluting Coronary Stent System. The ...
... 10 most promising drugs ... TSX Exchange Symbol: ... the "Company") (TSX:RVX) novel lead ApoA-I drug,candidate, RVX-208 has been ... (CVD) drugs available for strategic partnering by an,independent committee assembled ...
Cached Biology Technology:Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 2Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 2Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 4Industry Leaders Select Resverlogix's RVX-208 2Industry Leaders Select Resverlogix's RVX-208 3
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... bird flu virus H5N1 emerged in late 2005 and replaced ... southern China, despite an ongoing program to vaccinate poultry, according ... with scientists at St. Jude Children's Research Hospital. , The ... the increased occurrence of H5N1 poultry infections since October 2005, ...
... first large-scale analysis of proteins in the brains of ... and mechanisms that may one day lead to new ... in the current issue of Molecular Psychiatry, released on-line ... and point to profound changes in brain function related ...
... immune response to the 1918 influenza virus provides new ... in an article appearing online today in the journal ... 1918 virus triggers a hyperactive immune response that may ... their results suggest that it is the combination of ...
Cached Biology News:Control measures fail to stop spread of new H5N1 virus 2High-tech research shows cocaine changes proteins and brain function 2Mouse study reveals new clues about virulence of 1918 influenza virus 2Mouse study reveals new clues about virulence of 1918 influenza virus 3
MMP-1/8 (H-300)...
Gastric Carcinoma Marker [BY-1 (3H11)]...
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Biology Products: